NDT Advance Access first published online on March 15, 2005
This version published online on April 6, 2005
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfh761
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Silesian Medical University School, Nephrology Clinic, Zabrze, Poland
* To whom correspondence should be addressed. Background. Reducing the dosage frequency of subcutaneous epoetin in peritoneal dialysis (PD) patients is convenient and should improve patient satisfaction and, possibly, compliance. We investigated if a weekly dosage of epoetin Methods. After a 4 week run-in period, PD patients were switched to either weekly or fortnightly epoetin Results. The per-protocol cohort included 128 patients, of whom 54 received epoetin Conclusions. In stable PD patients switched from twice- or thrice-weekly to weekly epoetin
Received June 23, 2003
Accepted December 17, 2004
Original Articles
The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin
in peritoneal dialysis patients with chronic renal anaemia
2 Collegium Medicum, Jagiellonian University, Department of Nephrology, Krakow, Poland
3 Medical University School, Nephrology Clinic, Gdansk, Poland
4 Maggiore Hospital, Nephrology Division, Milan, Italy
5 Desio Hospital, Division of Nephrology and Dialysis, Desio, Italy
6 Association Altir, CHU Brabois, Vandoeuvre-de-Nancy, France
7 Hospital de la Paz, Nephrology Service, Madrid, Spain
8 University Hospital of Alexandroupolis, Nephrology Department, Alexandroupolis, Greece
Wladyslaw Grzeszczak, E-mail: wgrzeszczak{at}slam.katowice.pl
Abstract 
in PD patients safely maintained haemoglobin (Hb) concentrations equivalent to those obtained with previous twice- or thrice-weekly administration. In addition, we investigated if a fortnightly dosage of epoetin was safe and as effective as previous weekly administration. administration, depending on their previous treatment schedules, for 25 weeks. once weekly and 74 once fortnightly. The mean change in Hb concentration from baseline over weeks 13-25 and the 90% confidence intervals (CIs) remained within the target range (10-12 g/dl) and specified equivalence (±0.75 g/dl) limits in the weekly (-0.34 g/dl; 90% CI: -0.14 to -0.54 g/dl) and fortnightly (-0.39 g/dl; 90% CI: -0.24 to -0.55 g/dl) cohorts. The mean change from baseline in the epoetin dose was 1.4 IU/kg/week (90% CI: -3.8 to 6.6 IU/kg/week; 2%) in the weekly cohort and 4.4 IU/kg/week (90% CI: 1.7-7.2 IU/kg/week; 13%) in the fortnightly cohort. Both treatment regimens were well tolerated. treatment, Hb concentrations could be maintained within the specified range over 25 weeks without significant change in their mean epoetin doses. In patients switched from weekly to fortnightly treatment, Hb concentrations could also be maintained over 25 weeks. There was a small increase in the mean dose during this period, but 
50% of patients could be maintained without dose increase. Reducing dosage frequency may improve compliance in PD patients who self-administer their epoetin.
The publisher would like to apologise, as not all corrections were made before publication.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Robach, S. Recalcati, D. Girelli, C. Gelfi, N. J. Aachmann-Andersen, J. J. Thomsen, A. M. Norgaard, A. Alberghini, N. Campostrini, A. Castagna, et al. Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin Blood, June 25, 2009; 113(26): 6707 - 6715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-W. Fang and C.-H. Chang SUBCUTANEOUS ADMINISTRATION OF DARBEPOETIN ALFA EFFECTIVELY MAINTAINS HEMOGLOBIN CONCENTRATIONS AT EXTENDED DOSE INTERVALS IN PERITONEAL DIALYSIS PATIENTS Perit. Dial. Int., March 1, 2009; 29(2): 199 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Carrera, A. Disney, and M. Molina Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_4): iv19 - iv30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Schmitt, B. Nau, C. Brummer, J. Rosenkranz, and F. Schaefer Increased injection pain with darbepoetin-{alpha} compared to epoetin-{beta} in paediatric dialysis patients Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3520 - 3524. [Abstract] [Full Text] [PDF]
|
|